Incretin mimetic drugs such as glucagon-like peptide type 1 (GLP-1) receptor agonists (semaglitude) and dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor co-agonists (tirzepatide) not only improve glycemic control, but also provide additional benefits, such as weight reduction and an improved lipid profile [92], making them promising therapeutic options for patients with acromegaly. This evidence concerns the gene GCG and acromegaly.